BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVEC-HR RANDOMIZED CLINICAL TRIAL

被引：0
|
作者：
Guerrero-Ramos, Felix
Antonio Gonzalez-Padilla, Daniel
Gonzalez-Diaz, Alejandro
Villacampa-Auba, Felipe
Rodriguez-Izquierdo, Marta
Gomez-Canizo, Carmen
de la Rosa-Kehrmann, Federico
Rodriguez-Antolin, Alfredo
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD03-01
引用
收藏
页码：E72 / E72
页数：1
相关论文
共 50 条
  • [31] New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
    Asimakopoulos, Anastasios D.
    Kochergin, Maxim
    Colalillo, Gaia
    Fahmy, Omar
    Hassan, Fahmy
    Renninger, Markus
    Gallioli, Andrea
    Gavrilov, Pavel
    Gakis, Georgios
    [J]. BLADDER CANCER, 2023, 9 (03) : 237 - 251
  • [32] CHEMOHYPERTHERMIA WITH MITOMYCIN C AND COMBAT SYSTEM A NEW ALTERNATIVE TO BCB IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER?
    Plata Bello, Ana
    Villacampa, Felipe
    Diaz Goizueta, Javier
    Rios, Emilio
    Rimington, Peter
    Castillo, Jose
    Luis Pontones, Jose
    Nzeh, Cajetan
    Brisuda, Antonin
    Leon, Juan
    Chiancone, Francesco
    Hendricksen, Kees
    Voegell, Thomas-Alexander
    Wilby, Daniel
    Gonzalez-Padilla, Daniel
    Garcia Alvarez, Carlos
    Llanes, Luis
    Sousa, Alejandro
    Frank, Eric
    Castillo, D. J.
    Fedelini, Paolo
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E1119 - E1119
  • [33] Re-Tur plus BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: Rationale for a feasibility phase of a randomized controlled study
    Gontero, P.
    Soria, F.
    Burger, M.
    Comperat, E.
    Masson-Lecomte, A.
    Liedberg, F.
    Mostafid, H. A.
    Van Rhijn, B. W.
    Shariat, S. F.
    Marek, B.
    Sylvester, R. J.
    Palou, J.
    [J]. EUROPEAN UROLOGY, 2021, 79 : S454 - S455
  • [34] ADDING MITOMYCIN C TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER: A RANDOMISED PHASE 3 TRIAL
    Chalasani, V.
    Sengupta, S.
    Stockler, M.
    McCombie, S.
    Hawks, C.
    Long, A.
    Bracken, K.
    Roncolato, F.
    Hayne, D.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 53 - 53
  • [35] Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG und mitomycin C
    Gakis, Georgios
    [J]. AKTUELLE UROLOGIE, 2022, 53 (02) : 148 - 152
  • [36] Results of a randomized chemoprevention trial with fenretinide in non-muscle invasive bladder cancer
    Lerner, SP
    Sabichi, AL
    Grossman, HB
    Penson, DF
    Dinney, CPN
    Hemstreet, G
    Atkinson, EN
    Caraway, N
    Katz, R
    Lippman, SM
    [J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 246 - 247
  • [37] Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer
    Balar, Arjun, V
    Kamat, Ashish M.
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (09): : E380 - E380
  • [38] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Bashir Al Hussein Al Awamlh
    Sam S. Chang
    [J]. Current Oncology Reports, 2023, 25 : 83 - 91
  • [39] Genomic characterization of high-risk non-muscle invasive bladder cancer
    Meeks, Joshua J.
    Carneiro, Benedito A.
    Pai, Sachin G.
    Oberlin, Daniel T.
    Rademaker, Alfred
    Fedorchak, Kyle
    Balasubramanian, Sohail
    Elvin, Julia
    Beaubier, Nike
    Giles, Francis J.
    [J]. ONCOTARGET, 2016, 7 (46) : 75176 - 75184
  • [40] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
12345